Insmed Inc. (INSM) shares have surpassed the average analyst 12-month target price of $97.70, trading at $97.98, prompting investors to reassess the company's valuation. The consensus among 17 analysts is a "strong buy" rating, with targets ranging from $89.00 to $109.00, suggesting potential upside despite the stock exceeding the average target; investors must now determine if the valuation is stretched or if further gains are likely.
Insmed Inc. (INSM) shares have recently traded at $97.98, marginally exceeding the average analyst 12-month price target of $97.70. This event typically prompts analysts to either downgrade the stock due to valuation concerns or revise their target upwards if supported by positive fundamental developments. The current average target is derived from 17 distinct analyst estimates within the Zacks coverage universe, which exhibit a range from a low of $89.00 to a high of $109.00, with a standard deviation of $6.988. Despite the stock surpassing the average target, analyst sentiment remains overwhelmingly positive: there are 17 strong buy ratings and 1 buy rating, with no hold or sell ratings recorded over the past three months, resulting in an average rating of 1.06 (where 1 signifies a strong buy). This strong consensus suggests that analysts, on average, may still see further potential, although the current price level necessitates a careful re-evaluation by investors regarding INSM's valuation versus its growth prospects.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
